Peer Reviewed


Document Type


Publication Date



This material is based upon works supported by the Science Foundation Ireland under Grant SFI 08/RFP/CHE1563 and Equipment Grant 06/RFP/CHO024/EC07. The authors would also like to acknowledge RCSI for support under the Student Selected Component Programme (F. H.) and to thank Professor Celine Marmion (Pharmaceutical and Medicinal Chemistry Department, Royal College of Surgeons in Ireland) for the generous donation of A2780P cells, as well as Dr Yvonne Smith (Molecular and Cellular Therapeutics Department, Royal College of Surgeons in Ireland) and Ms Noémie Célard (Erasmus student, Pharmaceutical and Medicinal Chemistry Department, Royal College of Surgeons in Ireland) for their assistance during this work.


Antimicrobial Peptides (AMPs) have unique anticancer properties, but their clinical application is currently limited by an inadequate margin of safety. A prodrug strategy associated with a combination therapy approach could address this limitation by increasing their therapeutic index and their efficacy. Accordingly, the first targeted anticancer polymeric prodrug candidates of AMPs, intended for combination therapy with another polymeric prodrug of an approved antineoplastic agent (doxorubicin), were synthesized as either a PEG-based dual-release prodrug or two individual pegylated prodrugs. The latter are based on a cathepsin B-labile peptide linker and an acid-sensitive acyl hydrazone bond for the AMP and doxorubicin prodrugs, respectively. Anticancer activities and toxicity differentials achieved with the free peptide and its polymer conjugates against ovarian, cancer and non-malignant, cells, indicate that protease-dependent reversible pegylation could be implemented to increase the therapeutic indices of AMPs in cancer therapy. The results obtained also show that this approach can be developed if the releasable PEG linker can be optimised to conciliate the attributes and restrictions of pegylation against proteases. In addition, combination of the polymeric prodrugs of the AMP and of doxorubicin provides additive antitumor effects which could be exploited to enhance the efficacy of the AMP candidate.


Chemistry | Medicinal-Pharmaceutical Chemistry | Medicine and Health Sciences


Kelly GJ, Kia AF, Hassan F, O'Grady S, Morgan MP, Creaven BS, McClean S, Harmey JH, Devocelle M. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells. Organic & Biomolecular Chemistry. 2016;14(39):9278-9286.

PubMed ID


DOI Link


Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.